The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 02, 2018

Filed:

May. 31, 2017
Applicants:

Promab Biotechnologies, Inc., Richmond, CA (US);

Forevertek Biotechnology Co., Ltd., Changsha, Hunan, CN;

Inventor:

Lijun Wu, Albany, CA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12N 15/09 (2006.01); C12N 15/85 (2006.01); C12N 5/071 (2010.01); G01N 33/49 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); C07K 14/4748 (2013.01); C12N 5/0602 (2013.01); C12N 15/09 (2013.01); G01N 33/4915 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/70 (2013.01); C12N 2015/8572 (2013.01); C12N 2510/02 (2013.01);
Abstract

The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.


Find Patent Forward Citations

Loading…